HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

HUTCHMED Limited and AstraZeneca PLC have initiated a Phase II study of ORPATHYS®, an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction.